FDA issues key approvals in cardiology and endocrinology

Recent medical developments in cardiology and endocrinology have seen several significant regulatory milestones and clinical updates. In the field of cardiology, the FDA approved mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) in children weighing at least 30 kg. Additionally, the FDA has set a PDUFA date of June 18, 2027, for a subcutaneous GP IIb/IIIa inhibitor following phase 3 CeleBrate data.

In endocrinology, the FDA cleared Beta Bionics’ Mint insulin patch pump, a reusable and disposable system designed for diabetes management, which is expected to be available in early 2027. Bayer received FDA approval for a label expansion of finerenone (Kerendia) to treat chronic kidney disease associated with type 1 diabetes, marking a significant development for the condition. Other notable updates include the approval of efsitora alfa (Onswik) as a weekly insulin and various new drug approvals in the third quarter of 2026.